证券代码：301080 证券简称：百普赛斯 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 编号：2025-004 投资者关系活 动类别 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 及人员姓名 中欧基金、汇添富基金、招商基金、华泰柏瑞基金、永赢基金、嘉实基金、 富国基金、国盛证券、海通证券、德邦证券、招商证券等 67 家机构 72 名参 与人员 时间 2025 年 8 月 22 日 地点 上海 上市公司接待 人员 董事长、总经理 陈宜顶 副总经理、董事会秘书、财务负责人 林涛 投资者关系活 动主要内容介 绍 问：公司 2025 年半年度业绩？ 公司聚焦抗体药与细胞免疫治疗，集中优势资源推动核心业务发展，并 坚定不移地推进全球化战略。公司秉持"市场导向、客户至上、创新驱动"的 研发理念，持续加强重点与热点产品的研发力度，推出一系列高质量且契合 市场需求的产品，有效满足市场对重组蛋白等生物试剂不断增长需求。在内 部管理方面，公司进行全面优化，建立健全营销网络体系，全方位提升综合 竞争力与盈利能力。 2025 年上半年，公司实现营业收入 ...

Financial Performance - In 2024, the company achieved a revenue of 645.02 million CNY, a year-on-year increase of 18.65%, with overseas revenue (excluding specific acute respiratory disease-related products) growing over 20% [1] - For Q1 2025, the company reported a revenue of 186.49 million CNY, reflecting a year-on-year growth of 27.73%, and a net profit of 40.58 million CNY, up 32.30% [1] Business Strategy - The company focuses on biomedicine and cell immunotherapy, emphasizing a market-oriented, customer-first, and innovation-driven R&D approach [1] - A comprehensive internal management optimization has been implemented to enhance the marketing network and overall competitiveness [1] Global Operations - The company has established a logistics system covering nearly 80 countries and regions, serving over 10,000 industrial and research clients [3] - A robust internal communication mechanism supports seamless collaboration across global branches [3] Cell and Gene Therapy (CGT) - The company offers comprehensive solutions for CGT, leveraging its extensive protein pipeline and technical expertise [4] - Over 50 high-quality GMP-grade products have been developed, supporting clinical research and commercial production [6] Antibody-Drug Conjugates (ADC) - ADCs are highlighted as a key focus area, combining targeted antibodies with potent chemotherapy agents to enhance treatment efficacy while minimizing side effects [7] - The company provides a range of products and services for ADC development, covering the entire process from antibody preparation to quality control [8] Neuroscience Research - The company is actively involved in neuroscience, providing high-quality recombinant proteins and pre-formed fibrils (PFFs) for research on neurodegenerative diseases [9] - Products developed for Alzheimer's, Parkinson's, and Huntington's diseases support both treatment and diagnostic research [9]